Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
And there is £4!
NM
£3.59
£3.82 / £4.25 by year end.
RE: Friday ClubToday 10:35
Touraco £2.99
y11-shx £3.04
WMMG £3.06
nightyard £3.08
cw1966 £3.09
BP.ornot.2b £3.10
NSS £3.18
Sharefall £3.20
Android £3.23
KPMAN £3.23
oneyboy5000 - £3.25
Davross1 £3.25
slarti-bartfast £3.26
stockready1 £3.27
Winnerlot £3.28
BigMacCheese £3.30
Digby04 £3.31
Fox at £3.31
PANG £3.32
Spights £3.40
Longish £3.46
This is good news, but what will launch the share price will be a successful phase 3 trail. Should be due in the middle of the year. Based also on management share options that expire at around the same time, a success should see this in mid teens.
Sold out yesterday for a slight profit. Still a win. Will recover in time as economy improves but nothing in the short term specific to metro will push this on. Capital can be better used elsewhere. I also see no sign of tweedle dee and tweedle dum and their incoherent ramblings and references to their twitter handles. GLA
Institutional investors will definently drive this up, but could be a bit of a wait, since number of insitutions won't touch this because its related to cannibas still being an illegal drug for recreational use. Even though it's medical purposes, some institutions will not take the chance given the 'snowflake' environment that we now live in. A change in legislation would catapult this up. In the meantime, need good sales and revenues.
Punit - £10k is a very punchy investment and without rubbing it in, I hate to say it, not very smart. Obviously hindsight is a great thing. Unless of course you're a HNWI and losing £10k is not going to have any impact on you financially. This is the problem with AIM. Many people see the rises and are trying to do the trade of a lifetime, which will net them six or seven figures. It rarely happens. When i was much younger i only traded junior stocks. Looking back, it was akin to gambling. I now have a boring portfolio with 50% in Funds; 25% in ETFs and 20% in Large Cap Blue Chips. Remaning 5% is for sh*ts and giggles and i throw into stocks like KNB and MXC. I admit i got lucky last week and got in at 16 on day 1 and sold on Thursday into the rise at an ave of 42. That was completely down to luck. So I implore you, if you want to recoup some capital and want to deploy the remaining 45k, to stick it into a FTSE 2 x Long ETF tracker. If FTSE hits 7k, you'll make up for the 10k and it will get there at some point. GLA
Sorry, but too many people jumped into this without doing proper DD. All they saw was SP rising by the min and then FOMO took over, thinking that the rise would just increase and it would go to £1 or more. If you do happened to jump in without proper DD and relying on the surge, then don't get too greedy and take a small profit. Retrace was inevitable given that price on day 1 was 13p. Despite what the CEO was saying that this should be 60p, it is still up 100% on Day 1 price. An RNS, with evidence of increased sales and details of pilot in DE is what is needed to get this moving upwards. CBX IPO may also pull this up. Feel sorry for those who got in at the top and now in for the long term.
People have realised this has nothing to do with Bitcoin. but people should really do their research and not just jump onto a stock that has been clearly ramped up with misdirection. TRD are an IT Consultancy, that happens to have won a contract to support Blockchain projects.
Mirirk - This may well go down further and back to what the SP was before yesterday's RNS, since that is still a significant increase on IPO price. FOMO and day traders is what ramped the price up as high as 9p yesterday, coupled with the Kanabo rise and the fervour for Cannibas related stocks (i.e. CBD and recent Reddit driven spike for Cannibas stocks in US and Canada). Unless the volumes and demand continues, this is likely to go down without further news. I've tucked my holdings away (not insignificant but not too large so that in the event it doesn't work out, any losses aren't going to hurt too much) and won't be looking at them till closer to end of June, when we expect news. As we get closer to end of June, would expect price to rise expecting good news. Until then, forget about it and put your feet up. Or at the very least do some research and read the 2020 annual report and the recent investor presentation. GLA
M-Night - all sales are subject to successful phase 3 trials. Sales and distribution can only start then. They may welll be manufacturing them now in slovenia and getting them ready to be shipped to all SwissPharmaCan in readiness for distribution to buyers, but they can't be taken, whether as a food supplement or as a clinical prescription as an IMP. If Phase 3 is as successful as they believe, this will fly in my opinion. Fingers cross for these trials and as per my earlier post, the Exec Chairman and other employees have options that are due to expire end of june and what way to guarantee that they hit their strike price? A RNS confirming success is what! GLA
From the 2020 Annual report, the Exec Chairman personally has 5m options that are due to expire end of June 21. Which should coincide with Phase 3 trials of ArtemisC. These have a strike price of $0.15. Current share price is $0.125. Hence, $625k of shares that (based on $0.125 strike price) are dependant on the share price going higher than they are at the moment. There are just under another 15m options also due to expire in June of this year, which have $0.125 and another 10m options at $0.15. Options aren't always a definitive indicator of share price. Hence, not a given. Personally I've been given long dated options as part of my compensation package and there has been times when the share price hasn't performed and the options have lapsed. But in this case gives an indication of what Management think is achievable. Hence, bodes well for current SP being maintained in short term and a good base for it to go higher when phase 3 trial results come in. For me passing phase 3 trials and commencement of sales for yesterday's distribution agreement will be the moment that this SP will go much higher. So we have 3 months to wait. In the meantime, volume and speculation will drive it, up until the announcement of results. DYOR and GLA
Issue Date Expiry Date Exercise Price Number of options
2 & 23 March 2018 31 March 2021 $0.125 19,900,000
17 April 2018 30 June 2021 $0.15 10,000,000
2 April 2019 31 March 2021 $0.065 16,000,000
16 Sep 19 & 23 Dec 19 31 Aug 23 $0.05 17,500,000
16 Sep 19 & 23 Dec 19 31 Aug 23 $0.06 17,500,000
23 December 2019 31 August 2023 $0.07 17,500,000
12 May 2020 31 August 2023 $0.045 85,934,538
Total 184,334,538
Andrnz- sorry i don’t normally do this, but you’re having a laugh. Pressure is downward today after yesterday’s rise and also with the broader market. People who got in before yesterday last rise also cutting their losses.
ASX close mirrored LDN. Whichever exchange has the most shares in issue or volume dictates. Today's price will be simply dictated by simply economics 101. Supply and demand. GLA
Typo on last note. Lock in doesn’t apply to retail investors
Investin2020 - lock-ins tend to be for institutional investors or insiders who in return for free shares as part of remuneration or investing at discount are locked in. This also stops mass sell offs on day 1 and provides stability to price. This lock in does not apply to institutional investors. However you may not have shares in your nominated brokerage account on day 1 since this requires a transfer which may not be done in time for day 1. Be careful though. Given recent activity and volatility on these stocks, day 1 will be a roller coaster ride and given your questions, assume you’re a newbie, so only invest what you’re prepare to lose. As always DYOR
Munchbox - Sorry I misread your note. And you were referring to what MXC will get. Completely agree they will not see the full $41m, since that is retail cost and they would be selling at wholesale. I've looked at the RNS and couldn't see 30%. If 30% is their share, or $12m then fair enough, but at no point should investors think MXC will get $41m. That would be a school boy error.. This sounds about right since their partners will need to have their markup to make it worth their while. Key then is what is MXC break-even in terms of units that they need to sell and its simply PxV. Thats what is going to drive the SP. Key driver to move this share price forward is if they are able to announce increase orders and volumes. Next 3 months will be key, when Phase 3 trials complete and depending on the success of that trial, will drive orders. I'm happy with my smallish position, which was some profits from my KNB trade. Won't be adding any more till there is more updates. Having a small position means that i won't be watching it every minute like most people on this board. Only reason I'm looking at this and KNB earlier in the week was because I'm on holiday since it is half term! As always with junior stocks, don't bet the house on it. If you want to do that, go with boring FTSE shares with good Dividend yields! Logging out now and will look in, in a few weeks time.
Munchbox - where do you get 30% JV from? SwissPharma are the sole distrbutor. In the regions that they don't have a significant presence they are using local companies on the ground with a sales presence to distribute (e.g. Relay Medical and Glow Life in NA and the Caribbean). MXC are using SwissPharma's network. MXC will still be manufacturing the drug 100%. Up to SwissPharma to distribute in what way they see fit. As long as they get the orders in, MXC don't care. MXC just worry about R&D and Manufacturing. Please get your facts correct.